How much does lipitor typically lower heart disease risk?

Lipitor typically reduces major cardiovascular events by about 20–40 percent in high-risk patients. This range covers heart attacks, strokes, and related deaths.

How does this compare with other statins?
Atorvastatin at standard doses lowers LDL cholesterol more than simvastatin or pravastatin, which often translates into greater event reduction. Head-to-head trials show roughly 10–15 percent fewer events versus moderate-intensity statins.

What happens to risk when LDL drops further?
Each additional 1 mmol/L (39 mg/dL) reduction in LDL cuts major events by another 22 percent. Lipitor’s stronger LDL lowering therefore compounds its benefit in patients who start with very high cholesterol.

When does the benefit appear?
Risk reduction starts within the first year and continues to widen over five years. Most of the early gain comes from fewer heart attacks rather than strokes.

Who sees the biggest drop?
Patients with existing heart disease or diabetes gain the most; absolute risk reduction can reach 5–8 percentage points over five years. In lower-risk people the absolute benefit shrinks to 1–3 points.

Can the benefit be lost?
Stopping treatment reverses much of the LDL reduction within weeks, so risk climbs back toward baseline. Consistent daily use is needed to keep the protection.

How long does Lipitor’s patent protection last?
Pfizer’s main U.S. patent expired in 2011; generic atorvastatin is now widely available. [1]

Sources
[1] DrugPatentWatch.com — Atorvastatin entry: https://www.drugpatentwatch.com/drug/atorvastatin